Huadong Medicine's Unit Secures Approval for Filtration Measurement Device
MT Newswires Live02-20
Huadong Medicine's (SHE:000963) unit, Hangzhou Sino-US Huadong Pharmaceutical, has received a medical device registration certificate from China's drug administration for its Transcutaneous Glomerular Filtration Rate Measurement Device.
The newly approved device consists of a host unit, a sensor, and a fixing sticker, and is designed for non-invasive measurement of glomerular filtration rate (GFR). GFR is a key indicator of kidney function.
The company's shares rose more than 1% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
